SCIEX

The increase in non-monoclonal antibody protein drug candidates has required researchers to develop new methods. By adapting existing approaches find out how Dr. Stephen Lock is answering this challenge to better profile these extremely complex proteins. Wednesday, Sept. 2, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing until Sept. 2, 2021.

Join us for this webcast, in which Zuzana Demianova will present the analysis of low abundant mannose glycopeptides of adalimumab along with a highly sensitive peptide mapping analysis of adalimumab. Live: Wednesday, Aug. 26, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing until Aug. 26, 2021

Oligonucleotides are a chemically distinct class from small-molecule or protein therapeutics and present their own unique challenges for characterization and quantification. In this webcast you will learn how high-resolution mass spectrometry (HRMS) and microflow LC-MS can help you overcome these challenges and still maintain a high level of sensitivity. Live: Tuesday, March 17, 2020 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET On demand available after final airing until Mar. 17,, 2021 Register free

In the webcast, learn how using a high-resolution mass spectrometry-based approach can be a powerful analytical strategy to monitor and define multiple critical quality attributes (multi-attribute monitoring) of complex biomolecules in a single assay using a single instrument platform. Live: Thursday, Dec. 5, 2019 at 11am EST | 8am PST | 4pm GMT | 5pm CET On demand available after final airing until Dec. 5, 2020 Register free

Struggling to identify and quantify aspartate and iso-aspartate isomers and phosphorylated sites of proteins and peptides? Learn how Prof. Herbert Lindner uses CE-MS to tackle this challenge. Live: Thursday, Nov. 7, 2019 at 11am EST | 8am PST | 4pm GMT | 5pm CET On demand available after final airing Nov. 7, 2020 Register free

Solutions to address these challenges in the biopharmaceutical development process N-glycan screening for clone selection, characterization and process control

Dr. András Guttman presents a scoring approach for glycan similarity, referred to as Glycosimilarity Index, which can be used to aid in the rapid development of biosimilar products. Live: Wednesday, Aug. 21, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing Aug. 21, 2020 Register free

Aggregate analysis and charge variant analysis using a native MS approach allows rapid analysis of biotherapeutic critical quality attributes. Learn about these techniques from experts at Phenomenex and SCIEX. Live: Tuesday, Aug. 20, 2019 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Jul. 20, 2020 Register free

• CESI-MS is vital for nitrosamines analysis in post-harvest fumigation • Results of USDA testing of CESI-MS tools

• Background on capillary electrophoresis • Importance of glycan screening • Benefits of high-throughput screening with intuitive data analysis

With the recent legalization of cannabis in several states, there is a growing need for robust, reliable, and cost-effective analytical methods to facilitate routine testing for potency and contaminants. Here we present an LC–MS/MS method that uses the budget-friendly SCIEX Triple Quad 3500 LC–MS/MS system for the simultaneous detection and quantification of cannabinoids, pesticides, and mycotoxins in cannabis products using the Scheduled MRM algorithm.

SCIEX instruments have been designed with the production laboratory in mind. Our cannabis method was developed to allow the analysis for potency, pesticides and mycotoxins in one in injection. SCIEX also has a terpene method. All of your method requests for potency, pesticides and terpenes may be accomplished on one instrument.

Recently several states have legalized recreational and medical marijuana. This has created a confusing set of circumstances due to legalization at the state level, but cannabis is still an illegal schedule 1 drug at the federal level. This confusion also affects the development of analytical methods because there are no clear guidelines available to laboratories. This whitepaper will discuss the following topics: • Overview of state analytical requirements • Discussion of analytical method development for cannabinoids and related compounds of interest • Discussion of method performance